Zai Lab
Ella L. began their career as a Summer Analyst at PNC, where Ella worked on a project focusing on China-US foreign direct investments. Ella later moved on to Grant Thornton LLP as a Senior Associate, specializing in Strategic Solutions and M&A Practice. After gaining experience there, Ella transitioned to KPMG US as a Senior Associate in Deal Advisory & Strategy, focusing on the healthcare and life sciences sector. Currently, Ella is a Senior Manager in IR and Corporate Finance at Zai Lab, where Ella continues to leverage their expertise in the field.
This person is not in the org chart
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.